Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This is a research study to test the tolerability and clinical effectiveness of the study
drug, Letermovir (LET), when used as secondary prophylaxis following treatment of
Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.
This study is an open label trial in which Letermovir will be prescribed to prevent the
recurrence of CMV infection and disease in a solid organ transplant recipient following
treatment of CMV infection or disease.